Skip to main content
Clinical Trials/NCT00553709
NCT00553709
Terminated
Phase 2

The Role of Transcutaneous Nicotine in the Prevention of Postoperative Nausea and Vomiting in Non-smokers

University Hospital, Geneva1 site in 1 country200 target enrollmentOctober 2007

Overview

Phase
Phase 2
Intervention
Nicotine
Conditions
Postoperative Nausea and Vomiting
Sponsor
University Hospital, Geneva
Enrollment
200
Locations
1
Primary Endpoint
Prevention of PONV
Status
Terminated
Last Updated
16 years ago

Overview

Brief Summary

The purpose of this study is to determine whether nicotine is effective in the prevention of nausea and vomiting in non-smokers undergoing surgery

Registry
clinicaltrials.gov
Start Date
October 2007
End Date
August 2009
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Adults (18-80 years)
  • ASA I-II, non-smokers (or ex-smokers who have not been smoking for more than 2 years)
  • Undergoing elective surgery (ENT, abdominal, urological, gynaecological); and
  • Consenting to take part in the study will be included.

Exclusion Criteria

  • Smokers (cigarette, pipe, cigar)
  • Patients undergoing nicotine replacement therapy
  • Prolonged postoperative intubation
  • Postoperative nasogastric tube

Arms & Interventions

Nicotine patch

Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)

Intervention: Nicotine

Placebo patch

Placebo patch 10 cm2

Intervention: Nicotine

Outcomes

Primary Outcomes

Prevention of PONV

Time Frame: 48 hours postoperatively

Secondary Outcomes

  • Adverse effects that may be related to the nicotine patch, for instance, local skin reaction.(48 hours postoperatively)

Study Sites (1)

Loading locations...

Similar Trials